Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

卫喜康 - NMPA Drug Approval Details

Approvals/NMPA/Solifenacin Succinate Tablets

Approved

化学药品

Solifenacin Succinate Tablets

ASTELLAS PHARMA EUROPE B.V.🇨🇳 National Medical Products Administration

Approval Date: May 29, 2023
Approval ID: 8TEL7tyuFP5
Company: ASTELLAS PHARMA EUROPE B.V.
Type: 化学药品

Approval Details

Approval Id: 8TEL7tyuFP5
Approval Number: 国药准字HJ20140209
Generic Name: 琥珀酸索利那新片
Generic Name En: Solifenacin Succinate Tablets
Trade Name: 卫喜康
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 5mg
Reg Date: 2023-05-29
Expired Date: 2028-05-28
Company Name: ASTELLAS PHARMA EUROPE B.V.
Production Company Name: ASTELLAS PHARMA EUROPE B.V.
Company Detail Path: /organization/astellas-pharma-europe-b-v
Production Company Detail Path: /organization/astellas-pharma-europe-b-v

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

May 29, 2023

Approval ID

8TEL7tyuFP5

Type

化学药品

Back to NMPA Approvals